Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop

References

• Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012;119:1963–1971.
   PubMed Web of Science ®Google Scholar
• Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012;26:1895–1898.
   PubMed Web of Science ®Google Scholar
• Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012;119:4215–4223.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803–3809.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010;150:200–208.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose Ara-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (mcl.net). Blood 2010;116: Abstract 110.
   Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol 2012;30: Abstract 3.
   Web of Science ®Google Scholar
• Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008;113:108–116.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341–347.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011;12:361–368.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Rituximab with combination chemotherapy or bendamustine hydrochloride followed by consolidation chemotherapy and stem cell transplantation in older patients with previously untreated mantle cell lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01412879
   Google Scholar
• ClinicalTrials.gov. Rituximab, bendamustine hydrochloride, and bortezomib followed by rituximab and lenalidomide in treating older patients with previously untreated mantle cell lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01415752
   Google Scholar
• Beà S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009;113:3059–3069.
   PubMed Web of Science ®Google Scholar
• Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628–9632.
   PubMed Web of Science ®Google Scholar
• Rao E, Jiang C, Ji M, et al. The miRNA-17˜92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012;26: 1064–1072.
   Google Scholar
• Iqbal J, Shen Y, Liu Y, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012;119:4939–4948.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Lwin T, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010;115: 2630–2639.
   PubMed Web of Science ®Google Scholar
• Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43–50.
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762–765.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen X, Lin J, et al. Mcy represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012;31:3002–3008.
   PubMed Web of Science ®Google Scholar
• Wang X, Asplund AC, Porwit A, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008;143:248–252.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555–1562.
   PubMed Web of Science ®Google Scholar
• Chen YH, Gao J, Fan G, et al. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010;23:105–112.
   PubMed Web of Science ®Google Scholar
• Gustavsson E, Sernbo S, Andersson E, et al. SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. Mol Cancer 2010;9:187.
   PubMed Web of Science ®Google Scholar
• Vegliante MC, Royo C, Palomero J, et al. Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. PLoS One 2011;6:e21382.
   Web of Science ®Google Scholar
• Kuo P-Y, Leshchenko VV, Gellen TA, et al. High-resolution chromatin immunoprecipitation (ChIP) sequencing identifies novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. Blood 2011;118:abstract 585.
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Wang X, Asplund AC, Porwit A, et al. The subcellular Sox 11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Brit J Haematol 2008;143:248–52.
   PubMed Web of Science ®Google Scholar
• Flygare J, Gustafsson K, Kimby E, et al. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 2005;579:6885–6889.
   PubMed Web of Science ®Google Scholar
• Gustafsson K, Wang X, Severa D, et al. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 2008;123:1025–1033.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011;117:2423–2432.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012;122: 1066–1075.
   PubMed Web of Science ®Google Scholar
• Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007;179:2493–2500.
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010;28:4324–4332.
   PubMed Web of Science ®Google Scholar
• Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009;113:3546–3552.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117:530–541.
   PubMed Web of Science ®Google Scholar
• Horikawa M, Minard-Colin V, Matsushita T, et al. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest 2011;121:4268–4280.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427–1438.
   PubMed Web of Science ®Google Scholar
• Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006;66:7661–7167.
   PubMed Web of Science ®Google Scholar
• Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res 2008;68:5519–5523.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Lacasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012;119:4597–4607.
   PubMed Web of Science ®Google Scholar
• Huang X, Diliberto M, Jayabalan D, et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood 2012;120:1095–1106.
   PubMed Web of Science ®Google Scholar
• Epner E, Stuart A, Shimko S. Crosstalk between cyclins d1 and d3 in mantle cell level at the transcriptional and posttranscriptional levels. Blood 2011;118: Abstract 1373.
   Web of Science ®Google Scholar
• Bienvenu F, Jirawatnotai S, Elias JE, et alTranscriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature 2010;463:374–8.
   PubMed Web of Science ®Google Scholar
• Spurgeon S, Chen AI, Okada C, et al. A phase I/II study of vorinostat (SAHA), cladribine (2-Cda), and rituximab shows significant activity in previously untreated mantle cell lymphoma. Blood 2011;118: Abstract 441.
   Web of Science ®Google Scholar
• Zhang K, Pham LV, Zhang L, et al. Novel CRM-1 inhibitors for therapy in mantle cell lymphoma. Blood 2011;118: Abstract 2734.
   Google Scholar
• ClinicalTrials.gov. Safety study of the selective inhibitor of nuclear export (SINE) kpt-330 in patients with advanced hematological cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01607892.
   Google Scholar
• Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007;109:271–280.
   PubMed Web of Science ®Google Scholar
• Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004;305: 1466–1470.
   PubMed Web of Science ®Google Scholar
• Labelle JL, Katz SG, Bird GH, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest 2012;122:2018–2031.
   PubMed Web of Science ®Google Scholar
• Skak K, Kragh M, Hausman D, et al. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 2008;7:231–240. Erratum in: Nat Rev Drug Discov 2008;7:272.
   PubMed Web of Science ®Google Scholar
• Gowda A, Roda J, Hussain SR, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008;111: 4723–4730.
   PubMed Web of Science ®Google Scholar
• Smith MR, Joshi I, Jin F, et al. Murine model for mantle cell lymphoma. Leukemia 2006;20:891–893.
   PubMed Web of Science ®Google Scholar
• Beltran E, Fresquet V, Martinez-Useros J, et al. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. Proc Natl Acad Sci USA 2011;108:12461–12466.
   PubMed Web of Science ®Google Scholar
• Wang M, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 2011;118: Abstract 442.
   Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharma JP, et al. The Btk inhibitor ibrutinib (PCI-32765) has significant activities in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase p110δ in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116: Abstract 1777.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Neelapu SS, Kwak LW, et al. Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL). J Clin Oncol 2012;30: Abstract 2528.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011;12:361–368.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Rituximab, cladribine, and temsirolimus in treating patients with newly diagnosed mantle cell lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00787969.
   Google Scholar
• Hess G, Keller U, Atta J, et al. Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I/II trial. Blood 2011;118: Abstract 2697.
   Web of Science ®Google Scholar
• Witzig TE, Reeder CB, Plant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341–347.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study to investigate CAL-101 in combination with chemotherapeutic agents and CD20 mAb in patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma, mantle cell lymphoma or chronic lymphocytic leukemia. Available from: http://clinicaltrials.gov/ct2/show/NCT01088048.
   Google Scholar